Literature DB >> 8091362

[Aminoglycoside determinations calculated in endocarditis vegetations. Relations with clinical practices during infectious endocarditis treatment with amikacin].

M A Confesson1, X Barbaut, P Maire, J M Vergnaud, A el Brouzi, R W Jelliffe.   

Abstract

Using a new computer program SPHERE, amikacin concentrations have been computed at various layers of simulated endocardial vegetations. Inputs are the computed serum (central compartment) concentrations of either population pharmacokinetic models or of individualized patient-specific models utilizing Bayesian fitting to data of doses given and measured serum levels, using the USC*PACK PC Clinical Programs. The vegetation is modeled as an isotropic homogeneous sphere. Fick's second law of radial diffusion was applied to compute the in situ antibiotic concentrations. Examination of factors affecting concentrations in vegetations shows that in situ peak concentrations are less when the vegetation is larger, and when the antibiotic dose, serum concentrations and diffusivity are all less. The results show that early and aggressive treatment of infectious endocarditis is required with high doses of concentration-dependent antibiotics, such as aminoglycosides, to achieve the desired high peak serum levels and to reach effective concentrations deep inside the vegetations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8091362

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  2 in total

1.  In vivo antibacterial effects of simulated human serum profiles of once-daily versus thrice-daily dosing of amikacin in a Serratia marcescens endocarditis experimental model.

Authors:  D Bugnon; G Potel; Y Q Xiong; J Caillon; M F Kergueris; P Le Conte; D Baron; H Drugeon
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

2.  Bactericidal effect of pefloxacin and fosfomycin against Pseudomonas aeruginosa in a rabbit endocarditis model with pharmacokinetics of pefloxacin in humans simulated in vivo.

Authors:  D Bugnon; G Potel; Y Q Xiong; J Caillon; D Navas; C Gras; M F Kergueris; P Le Conte; F Jehl; D Baron; H Drugeon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-08       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.